Kirk E. Hevener, Pharm.D., Ph.D.

Assistant Professor, Pharmaceutical Sciences

MEMPHIS TN 381632198
Tel: (901) 448-1474

My Current CV


  • Postdoctoral Fellowship, University of Illinois at Chicago, Center for Pharmaceutical Biotechnology (2009-2013)
  • Postdoctoral Fellowship/Visiting Scientist, St. Jude Children''s Research Hospital, Chemical Biology and Therapeutics (2008-2009)
  • Ph.D., University of Tennessee Health Science Center, Pharmaceutical Sciences
  • Pharm.D., University of Tennessee Health Science Center, Pharmacy
  • B.S., Tennessee State University, Chemistry

Research Interests

Dr. Hevener''s laboratory research focuses on preclinical infectious diseases drug discovery, antimicrobial target validation and characterization, and structural mechanisms of bacterial resistance.  Current research areas include enzyme targets in the bacterial fatty acid synthesis pathway (FAS-II) and bacterial type 1a topoisomerases.  Areas of laboratory expertise include structure- and ligand-based drug discovery, computer-aided drug discovery, protein biochemistry, and structural biology.

Teaching Interests

Dr. Hevener''s teaching responsibilties include medicinal chemistry content in several areas of the professional pharmacy curriculum.  He also teaches graduate courses in Computer-Aided Drug Design and Cheminformatics & QSAR

Professional Interests

Dr. Hevener is an active member of the American Chemical Society, American Society for Microbiology, Society of Infectious Disease Pharmacists, American Association of Colleges of Pharmacy, Rho Chi (Pharmacy Honor Society), Phi Lambda Sigma (Pharmacy Leadership Society), and the Phi Delta Chi Professional Pharmacy Fraternity.

Recent Publications

  1. Recent Advances in the Rational Design and Optimization of Antibacterial Agents.  JA Jones, KG Virga, G Gumina, KE Hevener*.   MedChemComm. 2016, 7 (9), 1694-1715.  MedChemComm ‘Hot Article’
  2. Rifamycin Resistance in Clostridium difficile is Generally Associated with a Low Fitness.  Dang U, Zamora I, Hevener KE, Adhikari S, Wu X, Hurdle JG. Antimicrob Agents Chemother. 2016, 60 (9), 5604-5607.
  3. A simplified protocol for high-yield expression and purification of bacterial topoisomerase I. Jones JA, Price E, Miller D, Hevener KE*. Protein Expr Purif. 2016, 124, 32-40.
  4. Comparison of radii sets, entropy, QM methods, and sampling on MMPBSA, MMGBSA, and QM/MMGBSA ligand binding energies of F. tularensis enoylACP reductase (FabI).  Su PC, Tsai CC, Mehboob S, Hevener KE*, Johnson ME*. J Comp Chem. 2015, 36 (25), 1859-1873.
  5. Structural and Biological Evaluation of a Novel Series of Benzimidazole Inhibitors of Francisella tularensis Enoyl-ACP Reductase (FabI).  Mehboob S, Song J, Hevener KE, Su PC, Boci T, Brubaker L, Truong L, Deng J, Cook JL, Santarsiero BD, Ghosh AK, Johnson ME. Bioorg Med Chem Lett. 2015, 25 (6), 1292-1296.
  6. High-throughput screening (HTS) and hit validation to identify small molecule inhibitors with activity against NS3/4A proteases from multiple Hepatitis C Virus genotypes.  Lee H, Zhu T, Patel K, Zhang YY, Truong L, Hevener KE, Subramanya G, Gatuz JL, Sarkar A, Jeong HY, Uprichard SL, and Johnson ME. PLoS One. 2013, 8 (10), e75144.
  7. Hit Identification and Optimization in Virtual Screening: Practical Recommendations Based Upon a Critical Literature Analysis.  Tian Zhu, Shuyi Cao, Pin-Chih Su, Ram Patel, Darshan Shah, Heta B. Chokshi, Richard Szukala, Michael E. Johnson, Kirk E. Hevener*.  J Med Chem. 2013, 56 (17), 6560-6572.
  8. Synergistic Inhibitor Binding to the Papain-Like Protease of Human SARS Coronavirus: Mechanistic and Inhibitor Design Implications.  Lee H, Cao S, Hevener KE, Truong L, Gatuz JL, Patel K, Ghosh AK, and Johnson ME. ChemMedChem. 2013, 8 (8), 1361-1372.
  9. Fragment-based lead discovery using a multi-domain, parallel MM/PBSA simulation screening protocol.  Zhu T, Lee H, Lei H, Jones C, Patel K, Johnson ME, Hevener KE*.  J Chem Inf Model. 2013, 53 (3), 560-572.
  10. High-level expression, purification, and characterization of Staphylococcus aureus dihydrootase (PyrC) as a cleavable His-SUMO fusion.  Truong L, Hevener KE, Rice AJ, Patel K, Johnson ME, Lee H. Protein Expr Purif. 2013, 88 (1), 98-106.

Follow the Hevener Laboratory